openPR Logo
Press release

South-East Asia Rheumatoid Arthritis Therapeutics Market Expected To Increase In Value At A CAGR Of 4.7%, From $1.04 Billion To Over $1.4 Billion Till 2022

11-29-2017 10:29 AM CET | Health & Medicine

Press release from: Rheumatoid Arthritis Therapeutics Market

Market Research Report

Market Research Report

Researchmoz added Most up-to-date research on "South-East Asia Rheumatoid Arthritis Therapeutics Market Expected To Increase In Value At A CAGR Of 4.7%, From $1.04 Billion To Over $1.4 Billion Till 2022" to its huge collection of research reports.

Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. It is characterized by synovial inflammation and gradual bone erosion over many years. Disease progression results in stiffness and pain, especially in the hands and feet, which hinders mobility. Without treatment, the disease leads to joint destruction and disability.

The chronic nature of the disease, which requires ongoing treatment, and the relatively high annual cost of therapy (ACoT) have made RA treatment a highly lucrative market.

The RA therapeutic market has become very competitive due to the high number of new drug approvals. Competition is fierce, particularly among TNF-? inhibitors, which dominate the treatment market for RA patients who are refractory to traditional disease-modifying anti-rheumatic drugs (DMARD). Despite this, 30% of RA patients fail to attain a clinical response when treated with TNF-? inhibitors. However, other targeted programs, as well as newly marketed small-molecule DMARDs such as the Janus kinase (JAK) inhibitor Xeljanz (tofacitinib), have the potential to replace ineffective TNF-? inhibitors. Recently published study results of Xeljanz have shown a significant reduction in the risk of developing cardiac diseases such as heart attack and stroke in patients with RA.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1068036

Despite the superior efficacy of recently marketed therapies over traditional DMARD therapies, there is a need to improve safety in the therapeutic landscape. Elevated rates of infection are a frequent consequence of the immunosuppression involved in treatments, but this is required to suppress the autoimmune responses responsible for the symptoms of the condition. As a result, these biological therapies are not recommended to patients who are susceptible to infection.

In addition, there is a need to create biologics with more convenient and less invasive drug-delivery methods, as all existing therapies are administered subcutaneously or intravenously. These routes of administration are frequently associated with pain, rash, and allergic reactions at the injection or infusion site, and in the case of infusion flu-like illness, fever, chills, nausea, and headache. Therefore convenient and safe administration without significant compromise of therapy efficacy remains an unmet need.

Although the recently approved drug Xeljanz is an orally administered small-molecule drug, indicated as a second-line treatment for RA patients who have not shown an adequate response to methotrexate, and as a third-line therapy for patients who have not responded sufficiently to biologics, it carries a black-box warning in the US due to the safety issues of serious infections and malignancy.

Browse TOC @ https://www.researchmoz.us/rheumatoid-arthritis-therapeutics-in-southeast-asia-markets-to-2022-novel-jak-and-il6-receptor-inhibitors-to-stimulate-moderate-growth-despite-launch-of-biosimilars-of-blockbuster-antitnfs-report.html/toc

Scope

The current South-East Asia RA market contains novel products, including Xeljanz, a JAK inhibitor; and Actemra (tocilizumab), an IL-6 receptor inhibitor.

What are the competitive advantages of the existing novel drugs?

There are over 450 active pipeline molecules, and most of the late-stage investigational drug candidates feature improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.

Which classes of novel drugs are most prominent in the pipeline?
What is the potential for pipeline products to address unmet needs in the RA market?

Analysis of clinical trials since 2006 identified that the failure rates of RA molecules were highest in Phase II, at 72.6%, with the overall attrition rate for RA standing at 94.6%.

How do failure rates vary by stage of development, molecule type, and molecular target?
How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?

Over the 2015-2022 forecast period, the South-East Asia RA therapeutics market is expected to increase in value at a CAGR of 4.7%, from $1.04 billion to over $1.4 billion.

Which markets make the most significant contribution to the current market size?
What are the epidemiology trends in these markets?
Will new market entrants lead to substantial changes in annual therapy costs?
How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?

Rising RA prevalence population and the uptake of newer therapies will lead to significant market growth over the forecast period, despite the launch of biosimilars of blockbuster anti-TNFs.

Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs?

Reasons to buy

This report will enable you to -

Understand the clinical context of RA by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis and treatment guidelines and options.
Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.
Consider market opportunities and potential risks by examining trends in RA clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.
Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in RA by examining clinical trial data and multi-scenario product forecast projections.
Compare treatment usage patterns, annual therapy costs, and market growth projections for South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia.
Discover trends in licensing and co-development deals concerning RA products and identify the major strategic consolidations that have shaped the commercial landscape.

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
Follow us on LinkedIn @ http://bit.ly/1TBmnVG

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release South-East Asia Rheumatoid Arthritis Therapeutics Market Expected To Increase In Value At A CAGR Of 4.7%, From $1.04 Billion To Over $1.4 Billion Till 2022 here

News-ID: 836975 • Views:

More Releases from Rheumatoid Arthritis Therapeutics Market

Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022| Featuring Abbvie, Amgen, F. Hoffmann-La Roche, Johnson & Johnson & Pfizer
Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022| Featuring …
Researchmoz added Most up-to-date research on "Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs" to its huge collection of research reports. Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. It is characterized by synovial inflammation and gradual bone erosion over many years. Disease
Global Rheumatoid Arthritis Therapeutics Market to 2025| AbbVie, Boehringer Ingelheim, Novartis, Regeneron Pharmaceuticals, Pfizer, Bristol-Myers Squibb, F. Hoffmann-La Roche
Global Rheumatoid Arthritis Therapeutics Market to 2025| AbbVie, Boehringer Inge …
Researchmoz added Most up-to-date research on "Global Rheumatoid Arthritis Therapeutics Market Size, Status and Forecast 2019-2025" to its huge collection of research reports. In 2018, the global Rheumatoid Arthritis Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=2029591 This report focuses on the global
Asia-Pacific Rheumatoid Arthritis Therapeutics Market Anticipated to Witness Strong CAGR Value of 8.2% through 2023
Asia-Pacific Rheumatoid Arthritis Therapeutics Market Anticipated to Witness Str …
Globally, Rheumatoid Arthritis is one of the most common forms of arthritis. It is chronic, progressive and currently the incurable autoimmune disease that chiefly affects the joints. According to a recent analysis, Rheumatoid arthritis treatment market is expected to grow in coming years due to the increasing demand for more effective drugs and better medical facilities. To elaborate further, Market Research Hub (MRH) has publicized a study titled “Rheumatoid Arthritis

All 4 Releases


More Releases for South

Global Pajamas Market Report - Japan, Europe, South Korea, Asia and America ( No …
Recently we published the latest report on the Pajamas market. The report on the Pajamas market provides a holistic analysis, of market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 15 vendors. The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The Pajamas market analysis includes product segment and geographic landscape. The
South Africa Agriculture Market, South Africa Agriculture Industry, South Africa …
The South Africa has a market-oriented agricultural economy, which is much diversified and includes the production of all the key grains (except rice), deciduous, oilseeds, and subtropical fruits, sugar, wine, citrus, and most vegetables. Livestock production includes sheep, cattle, dairy, and a well-developed poultry & egg industry. Value-added activities in the agriculture sector include processing & preserving of fruit and vegetables, crushing of oilseeds, chocolate, slaughtering, processing & preserving of
South Korea Agriculture Market | South Korea Agriculture Industry | Covid-19 Imp …
Agriculture in South Korea may be a sector of the economy of South Korea. The natural resources needed for agriculture in South Korea aren’t torrential. Two thirds of the country are mountains and hills. Productive land solely accounts for 22 percent of the country's land. The foremost vital crop in South Korea is rice, secretarial regarding 90 percent of the country's total grain production and over 40 percent of farm
South Africa AdBlue Oil Market 2024: BASF SE (Germany), Engen Petroleum Ltd (Sou …
Market Snapshot The market for AdBlue oil in South Africa is expected to witness a CAGR of 4.83% during the assessment period assessment period (2017-2024). Adbule continues to be a popular fluid mix for diesel and gasoline fuel-based vehicles. The mix facilitates a selective catalytic reduction (SCR) technology along with other chemical reaction with the exhaust gases, effectively reducing the emmision of nitrogen oxides. Free Sample Report @ https://www.marketresearchfuture.com/sample_request/6223 This in turn
2018 Stem Cell Therapy Market by Top Key Players - Anterogen (South Korea), MEDI …
Adroit Market Research has announced the addition of the “Global Stem Cell Therapy Market Size Status and Forecast 2025”, The report classifies the global Stem Cell Therapy in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. This report studies the global Stem Cell Therapy Speaker market, analyzes and researches the Stem Cell Therapy Speaker development status and forecast in North
South America Aviation Market
The South American aviation market was affected adversely by the financial crisis, which had originated in the United States and the sales were impacted adversely by the same, but the market has recovered, since. Furthermore, the good performance of regional jets sold by Embraer were termed profitable by users and could certainly turn the tide as aircraft orders from other airlines continue to increase. Rising income levels in the continent